INTRODUCTION AND AIMS:
Peritoneal dialysis (PD) solutions using glucose as osmotic agent have been used for more than two decades as effective treatment for patients with end-stage renal disease. Although alternative osmotic agents such as amino acids and macromolecular solutions, including polypeptides and glucose polymers, are now available, glucose is still the most widely used osmotic agent in PD. It has been shown to be safe, effective, readily metabolized, and inexpensive. On the other hand glucose absorption from the peritoneal cavity may lead to the development of insulin resistance (IR). The aim of our study was to investigate the impact of PD initiation on the carbohydrate exchange disorders in non-diabetic end-stage renal disease (ESRD) patients. METHODS: A total of 15 patients with ESRD, who started treatment with continuous ambulatory peritoneal dialysis (CAPD) have been included in this longitudinal, observational cohort study. All patients were male, (the average age 49.6 6 5.9). Treatment with CAPD was performed using Dianeal PD 4 with a glucose concentration of 1.36% and 2.27% (Baxter Healthcare Corporation, USA). Patients were screened before initiation of PD, in 3 and 12 months of treatment. All patients were determined for the insulin, leptin and C-peptide blood levels using ELISA-method. The concentration of insulin was analyzed using antibodies against the human insulin molecule using the DRG Instruments GmbH (Germany) reagents. The Flexor junior biochemical analyser (The Netherlands) was used to study glucose. The insulin resistance index (HOMA-IR) (Homeostatic Model Assessment), which is characterized by the degree of insulin resistance, was calculated by the formula: level of insulin onset (lSO / ml) Â blood glucose onset (mmol / l) / 22.5. The IR was diagnosed with a HOMA index value of ! 2.77 unit. For the statistical analysis we used MedCalc. The normal distribution of data was verified using the Shapiro-Wilks criterion. The average values (M) and standard deviation (SD) or the median (Me) and interquartile ranges [Q25-Q75] were calculated according to a normal distribution. The Mann-Whitney (U) and Student's t-criterion were used to compare them. RESULTS: Among all ESRD patients examined before PD initiation significant increase of carbohydrate exchange rates investigated was shown. After 3 months of PD treatment inspected patients' blood insulin had decreased whereas leptin and C-peptide levels hadn't changed significantly. HOMA-IR after PD initiation had dropped by 63 % (tabl. 1). CONCLUSIONS: PD treatment during 12 months significantly reduces insulin resistance level in CKD stage V paients. Further research are needed to identify the influence of longterm treatment with glucose-containing solutions onto IR state among PD patients. 
Peritoneal dialysis (PD) effluent represents a rich source of molecular markers as novel tools for predicting clinical outcome and monitoring the therapy. Novel PD-fluids may enable patient-tailored interventions, such as peritoneal immunomodulation. High performance chromatographic and mass spectrometric methods allow assessment of molecular changes and therefore detection of candidate biomarkers from the abundant effluent. For understanding PD related processes on a systems biology level, a multi-level omics approach is particularly attractive. METHODS: The commercially available AbsoluteIDQV R p180 Kit (Biocrates, Austria) was used for metabolomic profiling of PD effluent of 20 stable PD patients obtained during a two-period, cross-over RCT (Eudract-2010-022804-29) . PD patients were treated either with standard PD fluid (Dianeal 3.86%, Baxter-Healthcare) or PDprotec TM (Dianeal with added alanyl-glutamine). The obtained metabolomic data were combined in a bioinformatic workflow with proteomic data from our recently established CPLL-FASP-TMT-LC/MS workflow in a multi-omics analysis for PD effluent from the same clinical samples. RESULTS: 188 small molecules, including free amino acids, acylcarnitines and glycerophospholipids, as well as custom metabolic indicators calculated from these metabolites were surveyed in a high throughput assay and correlated to treatment in the crossover trial and patient characteristics, such as time on PD therapy use of icodextrin and previous peritonitis. Together with proteomic data from 2506 individual proteins, coregulated biological processes such as oxidative stress responses were identified. Treatment with cytoprotective PD-protec TM rescued processes thought to be involved in decline of PD treatment efficiency and failing immune response. CONCLUSIONS: Metabolomic profiling of PD effluent proved to be a valuable approach for revealing small molecule related changes during PD treatment. The intervention with PD-protec TM as a cytoprotective PD-fluid does not only restore important immune processes, it is further reflected on small molecule responses such as indicators of oxidative stress in accordance with processes on the protein level. The exploitation of PD effluent information on multiple omics levels as identified by our bioinformatic approach has been shown to improve our understanding of the molecular processes in the peritoneal cavity and their role in development of complications for ultimately improving PD therapy.
FP478 PERITONEAL DIALYSIS IMPROVES QUALITY OF LIFE IN END-STAGE CONGESTIVE HEART FAILURE: A RANDOMIZED CLINICAL TRIAL
W. Janssen METHODS: 26 Patients with eCHF were randomized to additional PD (N¼17) or standard care alone (SC, N¼9) for 8 months. PD was started as overnight dwell (N¼8) or with both an overnight and day-time dwell of Extraneal (N¼9). During the study total dwell volumes between these approaches were similar. RESULTS: At baseline, patients were 74 6 7 (mean 6 SD) years of age, 62 % male with an estimated GFR of 31 6 15 ml/min and left ventricle ejection fraction (LVEF) of 27 6 6%. At baseline the PD group revealed a poorer performance as compared to SC with a higher NYHA class, lower SBP, worse LVEF, more patients with an ICD and shorter walking distance. Four patients in the PD group and two in the SC group died before their first trial visit at 2 months. None of these were related to PD implantation. Data of these patients were excluded from follow-up analysis. At 8 months 9 patients in the PD group were alive and 6 in the SC group. The PD group improved significantly more compared to SC in primary outcome NYHA class from baseline to 8 months (1.45 vs -0.17, p¼0.003). Changes in walking distance and PROMs were similar between the groups (walking, p¼0.3; PROMs, p¼0.6, respectively). Survival was not compromised by PD (p¼0.6). In the completed cases only, PD improved NYHA class and walking distance. In 1 patient NYHA significantly improved 1 class, in 4 patients 2 classes and in 1 patient 3 classes versus no improvement and even a deterioration in 1 patient in the SC group (repeated measures, p¼0.001). 6-Min walking distance improved gradually from 183 to 336 meters vs 183 to 209 meters in SC (p¼0.018). PROMs as measured by a rating score of perceived quality of life per day (ranging from 1 (bad) to 4 (good)) improved from 2.4 to 3.1 in PD and remained similar from 3.1 to 3.0 in the SC group. The groups did not differ significantly (p¼0.6). CONCLUSIONS: In conclusion, PD improves functional capacity and other quality of life related parameters versus SC in this first randomized trial in eCHF, particularly in patients with a life expectancy of more than 2 months. INTRODUCTION AND AIMS: Use of exchange devices for peritoneal dialysis (PD) fluids is common practice pattern in Japan. In the present investigation, we describe the exchange procedure for PD fluids and assess the association between exchange device for PD fluids use with peritonitis incidence using data from the Japan Renal Data Registry, a nationwide annual survey. METHODS: We retrospectively analyzed 3,594 patients aged 20 years or older receiving PD for more than 6 months at the end of 2013 with the information of exchange procedure for PD fluids and peritonitis incidence. Patients were categorized by exchange procedure for PD fluids, manual or device exchange groups. Peritonitis incidence is defined as a white blood cell count >¼ 100/uL (neutrophil>¼50%). Peritonitis incident rate (per patient-year) was calculated as follows: (peritonitis incidence in 2013 / total months on PD in 2013) Â 12. We applied Poisson regression analyses with a robust variance to estimate the incident rate ratio (IRR). Age, sex, PD vintage, body mass index, automated PD use, residual renal function, comorbidities, serum albumin, and haemoglobin were measured as potential confounders. Propensity score (PS) matching model was also performed as a sensitivity analyses. Multiple imputations using chained equation was used to estimate the models with missing covariates. RESULTS: Of 3,594 PD patients, 30.7% patients performed manual system, 69. 3% used devices (ultraviolet light irradiation 52.9%, sterile connecting device 14.9%, and others 1.5%) for PD fluids exchange. Shorter PD vintage, automated PD use, diabetes as comorbidities, and lower haemoglobin were associated with the use of exchange device for PD fluids. Crude peritonitis incident rates in overall, manual or device exchange groups were 0. 189, 0.169, and 0.196 (per patient-year) , respectively. Patients used devices for PD fluids exchange presented a tendency for increased risks of peritonitis incidence of 17% (IRR, 1.17, 95% CI, 1.01-1.37), 16% (IRR, 1.16, 95% CI, 0.99-1.37), and 18% (IRR, 1.18, 95% CI, 0.99-1.38) in crude, multivariate adjustment, and PS matching models, respectively. CONCLUSIONS: We did not find a favorable association between exchange devises for PD fluids and peritonitis incidence in the present investigation. There may remain possible residual confounding by indication of exchange procedure for PD fluids.
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FP480 LIPOPOLYSACCHARIDE (LPS) EVALUATION IN PERITONEAL DIALYSIS PATIENTS WITH PERITONITIS
Carlo Crepaldi
INTRODUCTION AND AIMS:
Bacterial peritonitis is a frequent complication during treatment of end-stage kidney disease by Peritoneal Dialysis (PD); severe or repeated episodes of peritonitis cause long-term complications that potentially lead to peritoneal membrane failure. Lipopolysaccharide (LPS) or endotoxin is an abundant glycolipid present on the outer membrane of Gram-negative bacteria and it may contribute to the progression of a local infection to sepsis. Previous studies demonstrated that LPS level is related to the degree of systemic inflammation and atherosclerosis in PD patients. The aim of this study was to evaluate LPS levels in PD patients, in particular, we investigated LPS levels in PD with Gram positive/ negative peritonitis. METHODS: We enrolled 49 PD (61% CAPD) patients: 37 with peritonitis and 12 without. None of the patients had signs and symptoms of sepsis. Peritoneal sample was collected for peritoneal WBC count (pWBC) and plasma samples were collected for WBC count, C-reactive protein (CRP) and interleukins evaluation (IL6, IL1b and IL8) on the first day of peritonitis. Peritonitis was defined according to the criteria of the International Peritoneal Dialysis Society Guidelines. Quantitative determination of LPS was performed by ELISA Kit according to manufacturer's instructions in peritoneal and plasma samples. Statistical analysis was performed using the SPSS Software package. A p-value of <0.05 was considered statistically significant RESULTS: Quantitative analysis of peritoneal and plasma LPS showed significantly higher levels in PD patients with peritonitis compared to patients without (p¼0.001). Furthermore, we divided patients with peritonitis in 2 groups on the basis of Gram staining (Gram positive¼27; Gram negative¼14). Peritoneal and plasma LPS levels showed significantly lower levels in PD patients with Gram positive peritonitis than in patients with Gram negative (p¼0.001). The median level of LPS showed no significant differences between patients without peritonitis and with Gram positive peritonitis (p¼0.195). On the contrary, LPS levels showed significantly higher levels in PD patients with Gram negative peritonitis compared to patients without peritonitis (p¼0.001) (Figure) . A significant positive correlation was observed between pWBC and peritoneal LPS (Spearman's rho¼0,412, p¼0.013). However, no statistically significant
